secreted protein acidic and cysteine richGenealiases: BM-40 · OI17 · ON · ONT
Q-omics provides the consensus-scored SPARC profile across patient tissues and cancer cell-line models. SPARC expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SPARC is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SPARC protein abundance shows 25,583 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, HNSC, and PDAC as cancer lineages where SPARC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPARC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPARC survival associations across molecular data types. SPARC RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPARC RNA expression–survival associations across cancer types. High SPARC expression shows unfavorable associations in UVM, MESO, ACC, STAD and BLCA, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SPARC RNA expression.
This table summarizes SPARC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPARC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPARC shows higher tumor expression in HNSC, KIRC, COAD, LIHC, STAD and THCA. The HNSC box plot shows higher SPARC RNA expression in tumor versus normal tissue (log2 FC = +4.511, t-test p < 0.001).
This table shows molecular features associated with SPARC in patient tissues and cancer cell lines. In patient samples, SPARC shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPARC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
